Trial Profile
Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidaemia; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms CARES
- Sponsors SCYNEXIS
- 14 Aug 2023 According to a SCYNEXIS media release, interim data from this trial presented at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023
- 25 Jun 2023 Status changed from active, no longer recruiting to completed.
- 12 May 2023 According to Scynexis media release, company has announced the closing of its previously announced exclusive license agreement with GSK plc. Under the license agreement, SCYNEXIS will continue executing the Phase 3 program for invasive candidiasis (IC).